In this
work, some new oxadiazole derivatives have been prepared, by reacting phenyl
hydrazine and acetic anhydride together, which furnished 2,4-dimethyl-4-phenyloxadiazole.
This product was reacted with a series of aromatic aldehydes, to obtain a
series of oxadiazole derivatives. These derivatives were characterized by TLC, melting points, infrared red, proton nuclear
magnetic resonance, carbon thirteen nuclear magnetic resonance and mass
spectroscopy. Finally, these synthetized
derivatives were tested for antiproliferative activity by two different
cell lines. MCF-7 (Breast cancer cell line) and HepG2 (Liver cancer cell line)
were used to assess the antiproliferative activity of the prepared compounds.
References
[1]
Bridges, A.J. (2001) Chemical Inhibitors of Protein Kinases. Chemical Reviews, 101, 2541-2572. https://doi.org/10.1021/cr000250y
[2]
Wang, J.D., Miller, K., Boschelli, D.H., Ye, F., Wu, B., Floyd, M.B., Powell, D.W., Wissner, A., Weber, J.M. and Boschelli, F. (2000) Inhibitors of Src Tyrosine Kinase: The Preparation and Structure Activity Relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazolines. Bioorganic & Medicinal Chemistry Letters, 10, 2477-2480. https://doi.org/10.1016/S0960-894X(00)00493-5
International Agency for Cancer Research and World Health Organization (2014) World Cancer Factsheet 2014. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2014.html
[5]
Salem, M., Ayyad, R., Sakr, H. and Gaafer, A. (2022) Design and Synthesis of New Compounds Derived from Phenyl Hydrazine and Different Aldehydes as Anticancer Agents. International Journal of Organic Chemistry, 12, 28-39. https://doi.org/10.4236/ijoc.2022.121003
[6]
Cai, S.X. (2007) Small Molecule Vascular Disrupting Agents: Potential New Drugs for Cancer Treatment. Recent Patents on Anti-Cancer Drug Discovery, 2, 79-101. https://doi.org/10.2174/157489207779561462
[7]
Shi, L.M., Fan, Y., Lee, J.K., Waltham, M., Andrews, D.T., Scherf, U., Paull, K.D. and Weinstein, J.N. (2000) Mining and Visualizing Large Anticancer Drug Discovery Databases. Journal of Chemical Information and Modeling, 40, 367-379. https://doi.org/10.1021/ci990087b
[8]
Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Wolff, V.A., Goodrich, M.G., Campbell, H., Mayo, J. and Boyd, M.J. (1991) Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines. Journal of the National Cancer Institute, 83, 757-766. https://doi.org/10.1093/jnci/83.11.757
[9]
Palmer, B.D., Rewcastle, G.W., Atwell, G.J., Baguley, B.C. and Denny, W.A. (1988) Potential Antitumor Agents. 54. Chromophore Requirements for in Vivo Antitumor Activity among the General Class of Linear Tricyclic Carboxamides. Journal of Medicinal Chemistry, 31, 707-712. https://doi.org/10.1021/jm00399a003
[10]
Denny, W.A., Rewcastle, G.W. and Baguley, B.C. (1990) Potential Antitumor Agents. 59. Structure-Activity Relationships for 2-Phenylbenzimidazole-4-Carboxamides, a New Class of Minimal DNA-Intercalating Agents Which May Not Act via Topoisomerase II. Journal of Medicinal Chemistry, 33, 814-819. https://doi.org/10.1021/jm00164a054
[11]
Lang, D.K., Kaur, R., Arora, R. Saini, B. and Arora S. (2020). Nitrogen-Containing Heterocycles as Anticancer Agents: An Overview. Anti-Cancer Agents in Medicinal Chemistry, 20, 2150-2168. https://doi.org/10.2174/1871520620666200705214917
[12]
Sakr, H.M., Ayyad R.R., Mahmoud, K., Mansour, A.M. and Ahmed, A.G. (2021) Design Synthesis of Analgesics and Anticancer of Some New Derivatives of Benzimidazole. International Journal of Organic Chemistry, 11, 144-169. https://doi.org/10.4236/ijoc.2021.113011
[13]
Khalifa, M.M., Sakr, H.M., Ibrahim, A., Mansour A.M. and Ayyad R.R. (2022) Design and Synthesis of New Benzylidene-Quinazolinone Hybrids as Potential Anti-Diabetic Agents: In Vitro α-Glucosidase Inhibition, and Docking Studies. Journal of Molecular Structure, 1250, Article ID: 131768. https://doi.org/10.1016/j.molstruc.2021.131768
[14]
El-Helby, A., Sakr, H.M., Ayyad R.R. and Mahdi, H. (2020) Design, Synthesis, Molecular Modeling, in Vivo Studies and Anticancer Activity Evaluation of New Phthalazine Derivatives as Potential DNA Intercalators and Topoisomerase II Inhibitors. Bioorganic Chemistry, 103, Article ID: 104233. https://doi.org/10.1016/j.bioorg.2020.104233
[15]
Ayyad, R.R. (2012) Synthesis and Biological Evaluation of Novel Iodophthalazinedione Derivatives as Anticonvulsant Agents. Al-Azhar Journal of Pharmaceutical Sciences, 45, 1-13. https://doi.org/10.21608/ajps.2012.7146
[16]
El-Dehna, W.M. Abou-Seri, S., El-Kerdawy, A. and Ayyad, R.R. (2016) Increasing the Binding Affinity of VEGFR-2 Inhibitors by Extending Their Hydrophobic Interaction with the Active Site: Design, Synthesis and Biological Evaluation of 1-Substituted-4-(4-Methoxybenzyl) Phthalazine Derivatives. European Journal of Medicinal Chemistry, 113, 50-62. https://doi.org/10.1016/j.ejmech.2016.02.029
[17]
El-Helby, A., Ayyad, R.R., Sakr, H.M. and Abdul-Rahim, A.S. (2017) Design, Synthesis, Molecular Modeling and Biological Evaluation of Novel 2,3-Dihydrophthalazine-1,4-Dione Derivatives as Potential Anticonvulsant Agents. Journal of Molecular Structure, 1130, 333-351. https://doi.org/10.1016/j.molstruc.2016.10.052
[18]
El-Helby, A., Ayyad, R.R., Sakr, H.M., El-Adl, K. and Ali, M.M. (2017) Design, Synthesis, Molecular Docking, and Anticancer Activity of Phthalazine Derivatives as VEGFR-2 Inhibitors. Archiv der Pharmazie, 350, Article ID: 1700240. https://doi.org/10.1002/ardp.201700240
[19]
El-Helby, A., Ayyad, R.R., El-Adl, K. and El-Kady H. (2019) Phthalazine-1, 4-dione Derivatives as Non-Competitive AMPA Receptor Antagonists: Design, Synthesis, Anticonvulsant Evaluation, ADMET Profile and Molecular Docking. Molecular Diversity, 23, 283-298. https://doi.org/10.1007/s11030-018-9871-y
[20]
Eissa, I.H., Metwally, A.M., Belal, A. and Mehany A.B. (2019) Discovery and Antiproliferative Evaluation of New Quinoxalines as Potential DNA Intercalators and Topoisomerase II Inhibitors. Archiv der Pharmazie, 352, Article ID: 1900123. https://doi.org/10.1002/ardp.201900123
[21]
Kamal, I.M., Abdul-Rahman, A.A., Ayyad R.R. and El-Adl, K. (2013) Design and Synthesis of Some Novel 2-(3-methyl-2-oxoquinoxalin-1(2H)-yl)-N-(4-(substituted)phenyl) Acetamide Derivatives for Biological Evaluation as Anticonvulsant Agents. Bulletin of Faculty of Pharmacy, Cairo University, 51, 101-111. https://doi.org/10.1016/j.bfopcu.2012.11.003
[22]
El-Helby, A., Ayyad, R.R. and Zayed, M.F. (2011) Synthesis and Biological Evaluation of Some Novel Quinoxaline Derivatives as Anticonvulsant Agents. Arzneimittelforschung, 61, 379-381. https://doi.org/10.1055/s-0031-1296214
[23]
El-Helby, A., Ayyad R.R., El-Adl, K. and El-Wan, A. (2017) Quinoxalin-2 (1H)-One Derived AMPA-Receptor Antagonists: Design, Synthesis, Molecular Docking and Anticonvulsant Activity. Medicinal Chemistry Researchs, 26, 2967-2984. https://doi.org/10.1007/s00044-017-1996-5
[24]
El-Helby, A., Ayyad R.R., Zayed, M.F. and Abou-El-Kheer H.S. (2019) Design, Synthesis, in Silico ADMET Profile and GABA-A Docking of Novel Phthalazines as Potent Anticonvulsants. Archiv Der Pharmazie, 352, Article ID: 1800387. https://doi.org/10.1002/ardp.201800387
[25]
El-Helby, A., Ayyad, R.R., Sakr, H.M. and El-Adl, K. (2018) Design, Synthesis, In Vitro Anti-Cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo [3,4-a] Phthalazine Derivatives Targeting VEGFR-2 Enzyme. Anti-Cancer Agents in Medicinal Chemistry, 18, 1184-1196. https://doi.org/10.2174/1871520618666180412123833
[26]
Ekhlass, M.N., Abdul Razek F.M., Ayyad R.R. and El-Farargy, A.F. (2016) Synthesis and Some Reactions of 1-aryl-4-acetyl-5-methyl-1, 2, Triazole Derivatives with Anticonvulsant Activity. Mini-Reviews in Medicinal Chemistry, 16, 926-936. https://doi.org/10.2174/1389557516666160118105505
[27]
Ayyad R.R. (2014) Synthesis and Anticonvulsant Activity of 6-Iodo Phthalazinedione Derivatives. Al-Azhar Journal of Pharmaceutical Sciences, 50, 43-54. https://doi.org/10.21608/ajps.2016.6930
[28]
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J. and Vistica, D. (1990) New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening. Journal of the National Cancer Institute, 82, 1107-1112. https://doi.org/10.1093/jnci/82.13.1107
[29]
Allam, R.M., Al-Abd, A.M., Khedr, A. and Sharaf, O.A. (2018) Fingolimod Interrupts the Cross Talk between Estrogen Metabolism and Sphingolipid Metabolism within Prostate Cancer Cells. Toxicology Letters, 11, 77-85. https://doi.org/10.1016/j.toxlet.2018.04.008
